Selective deletion of Jak2 in adult mouse hematopoietic cells leads to lethal anemia and thrombocytopenia
Year: 2014
Type: article
Abstract: Jak2 inhibitors are commonly used in the treatment of patients with myeloproliferative neoplasms, in particular patients with primary myelofibrosis and splenomegaly.[1][1] The currently available Jak2 inhibitors do not distinguish between wild-type (WT) Jak2 and mutant Jak2-V617F. Although a modest
Source: Haematologica
Institutions: University Hospital of Basel, University of Nebraska at Omaha
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $2,157
OpenAlex ID: W2047345981
